Takeda divests select OTC to STADA for $660M
Singapore, Nov. 5 -- Takeda Pharmaceutical Company Limited has announced that it has entered into an agreement to divest a portfolio of select products to STADA Arzneimittel AG, an international pharmaceutical company, for a total value of $660 million. The portfolio includes over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States, which form part of Takeda's Growth & Emerging Markets Business Unit.
This is Takeda's fourth divestment transaction in the past six months that contributes to the Company's goal to divest approximately $10 billion in non-core assets to focus on its five key business areas and commitment to accel...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.